CompanyCLDI CLDWWNYSE, OTCSan Diego, CA

Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics develops oncolytic virotherapy using its RedTail platform for systemic delivery of genetic medicines to metastatic tumors.

SEC EDGAR ClinicalTrials.gov calidibio.com

8-KSep 25Latest SEC filing

Sep 22Latest story

September 2026

Calidi Biotherapeutics closes $1.2 million registered direct stock offering

Sep 22PartnershipCalidi Biotherapeutics, Inc.

Calidi Biotherapeutics prices $1.2 million stock offering at $1.17 per share

Sep 17FinancingCalidi Biotherapeutics, Inc.

August 2026

Calidi gets FDA pre-IND feedback on CLD-401, still targets Q1 2027 first dose

Aug 13Quarterly updateCalidi Biotherapeutics, Inc.

July 2026

Calidi Biotherapeutics signs new San Diego lease, ends current one early

Jul 16PartnershipCalidi Biotherapeutics, Inc.